Industry Outlook
Paget’s disease treatment market is projected to grow at a CAGR of 3.4% during the forecast period from 2025 to 2033. Paget’s disease of bone affects the way that bone is renewed & repaired, during this process an uncontrolled level of bone generation occurs that results into an abnormal bone formation. The affected bone is weaker than normal and leads to a bend or deformity making that bone fragile. According to Arthritis Research UK, Paget’s disease is identified as the most common disease in UK and also observed in people from Southern & Western Europe including other countries such as Australia & New Zealand. In addition to that around 2 to 3 people in 100 and aged above 50 have Paget’s disease.
"Bisphosphonate is the most preferred drug class against Paget’s disease and will maintain its dominance throughout the forecast period"
In 2021, Bisphosphonates were identified as the largest segment being the first choice of medical practitioners and increasing awareness related to Paget’s disease. Bisphosphonates are a vital class of drugs that tackles Paget’s disease by decreasing destruction of abnormal osteoclastic bone. In addition, bisphosphonates usually get settled in the bone; the advantage may last for several months or years and if given in the early stages, may prevent further complications.
"Europe is the fastest growing market due to rising awareness in of Paget’s disease in medical practitioners and increasing diagnostic rates"
During the forecast period from 2025 to 2033, Europe expected to be the fastest growing Paget’s disease treatment market specifically due to increasing awareness in medical practitioners related to rare disorders, and developed healthcare infrastructure is supporting the rise in diagnosis rate. According to market experts, rising geriatric population in U.K. and highest prevalence rate of 4.6% makes it the most prevalent country globally. Thus, in the near future Europe expected to surpass North America and dominate the market during the forecast period from 2025 to 2033.
Historical & Forecast Period
This study report represents analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Paget's Disease Treatment market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
ATTRIBUTE | DETAILS |
---|---|
Research Period | 2023-2033 |
Base Year | 2024 |
Forecast Period | 2025-2033 |
Historical Year | 2023 |
Unit | USD Million |
Segmentation | |
Drug Class
| |
Region Segment (2023-2033; US$ Million)
|
Key questions answered in this report